Drug Development

Search documents
Corvus Pharmaceuticals (CRVS) 2025 Conference Transcript
2025-06-05 14:20
Corvus Pharmaceuticals (CRVS) 2025 Conference June 05, 2025 09:20 AM ET Speaker0 Alright. Welcome, everyone, to Jefferies twenty twenty five, global health care conference. My name is Roger Song, one of the senior analysts covering semi cap biotech in The US. It's my pleasure to introduce our next printing company covers. We have the CEO, Rich Miller. Speaker1 Thank you Roger and good morning everyone. I want to thank Jeffries for the invitation to the healthcare conference and thank you all for attending. ...
Moleculin Releases On-Demand KOL Webcast to Discuss Data from its Phase 1B/2 Study of Annamycin for the Treatment of Soft Tissue Sarcoma (STS) Lung Metastases (MB-107)
Globenewswire· 2025-06-05 12:00
Access the on-demand webcast here HOUSTON, June 05, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viruses, today announced the release of its Soft Tissue Sarcoma (STS) Lung Mets KOL Webcast discussing the final data from its U.S. Phase 1B/2 clinical trial evaluating Annamycin as monotherapy for the treatment of soft tissue sarcoma lung metastase ...
Gilead Sciences (GILD) 2025 Conference Transcript
2025-06-04 16:07
Gilead Sciences (GILD) 2025 Conference June 04, 2025 11:05 AM ET Speaker0 Good morning everyone. Welcome to our next panel discussion with Gilead Sciences. We have a couple of important members of the executive team from Gilead here up with us. To my left, Dietmar Berger, who's the new CMO, and I like to say running the hot seat of R and D in front of Wall Street to talk about obviously everything going on in the pipeline. As well as Cindy Paretti. She's Executive Vice President of Kite and runs everything ...
Rapport Therapeutics (RAPP) 2025 Conference Transcript
2025-06-04 15:32
Summary of Rapport Therapeutics (RAPP) 2025 Conference Company Overview - **Company**: Rapport Therapeutics (RAPP) - **Industry**: Biotechnology, specifically in precision neuroscience and epilepsy treatment - **Key Personnel**: Abe Cisse (CEO), Choi Ignelzi (CFO) [1][2] Core Points and Arguments - **Vision**: Rapport aims to be a leading precision neuroscience company, focusing on receptor associated proteins to develop targeted therapies [4][5]. - **Lead Program**: RAP-two 19, an AMPA TARP gamma-eight modulator, targets specific brain areas to modulate AMPA receptors, aiming to reduce adverse effects (AEs) associated with traditional anti-seizure medications [5][6]. - **Clinical Trials**: - Currently conducting a Phase 2a proof of concept study for RAP-two 19 in focal epilepsy, fully enrolled with 30 patients, with data expected in September 2025 [7][8]. - Plans to explore RAP-two 19 in bipolar mania and peripheral neuropathic pain, with a long-acting injectable formulation also in development [8][9][10]. - **Differentiation**: RAP-two 19 is designed for once-daily dosing with a long half-life, aiming to minimize drug-drug interactions (DDIs) and improve patient adherence [12][14][15][16]. Important Data and Metrics - **Phase 1 Studies**: Completed four studies with 100 healthy volunteers, showing a favorable tolerability profile and high receptor occupancy (up to 85%) without significant sedation or motor impairment [23][24]. - **Efficacy Expectations**: The primary endpoint for the Phase 2a study is a 30% reduction in long episodes of seizures, with a target responder rate of at least 40% [38][39]. - **Safety Profile**: No serious adverse events (SAEs) reported; mild AEs observed were transient and resolved on their own [45][46]. Additional Insights - **Biomarker Utilization**: The study leverages an implantable RNS device to capture EEG activity, providing an objective measure of efficacy compared to traditional seizure diaries [28][30]. - **Regulatory Pathway**: The company plans to conduct two registrational trials for NDA submission, with the potential to start in 2026 [51][52]. - **Market Positioning**: The combination of efficacy, tolerability, and administration profile positions RAP-two 19 as a potentially best-in-class therapy for epilepsy [41][44]. Conclusion Rapport Therapeutics is advancing its lead program RAP-two 19 with a focus on precision neuroscience, aiming to address significant unmet needs in epilepsy treatment through innovative clinical trial designs and a differentiated safety profile. The upcoming data readout in September 2025 will be critical for the company's future development plans and market positioning.
Teva Pharmaceutical Industries (TEVA) 2025 Conference Transcript
2025-06-04 14:20
Teva Pharmaceutical Industries (TEVA) 2025 Conference June 04, 2025 09:20 AM ET Speaker0 Good morning. Welcome to the Jefferies Healthcare Conference in New York, day one. My name is Dennis Thing, biotech analyst, here at Jefferies. I have the great pleasure of having Teva here with us. Welcome. So maybe to I think there's a little bit of feedback, but maybe just help level set us in terms of where the business is right now and how the business has evolved over the last several years and some of the investm ...
PTC Therapeutics (PTCT) FY Earnings Call Presentation
2025-06-03 14:54
PTC Therapeutics June 2025 Matthew B. Klein, MD CEO Pam and Kelsey living with PKU 1 Corporate Presentation – June 2025 Forward Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this presentation, other than statements of historic fact, are forward-looking statements, including statements regarding: the future expectations, plans and prospects for PTC, including with respect to the ...
Nxera Pharma Achieves Development Milestone in Collaboration with Eli Lilly Targeting Metabolic Diseases
Globenewswire· 2025-06-01 23:30
Core Insights - Nxera Pharma has achieved a significant development milestone in its collaboration with Eli Lilly, which is expected to result in a milestone payment in Q3 of the fiscal year ending December 2025 [1][2] - The collaboration, initiated in 2022, leverages Nxera's GPCR-focused drug design capabilities alongside Lilly's expertise in development and commercialization [2] - Nxera is eligible for up to US$694 million in development and commercial milestones, in addition to tiered royalties on global sales [3] Company Overview - Nxera Pharma is a biopharma company focused on developing specialty medicines for unmet medical needs, particularly in Japan and the broader APAC region [5] - The company has an extensive pipeline of over 30 active programs targeting areas such as neurology, metabolic diseases, and immunology, utilizing its proprietary NxWave™ discovery platform [6] - Nxera employs approximately 400 people across key locations including Tokyo, Osaka, London, Cambridge, Basel, and Seoul [7]
Cybin (CYBN) Fireside Chat Transcript
2025-05-29 16:00
Cybin (CYBN) Fireside Chat May 29, 2025 11:00 AM ET Speaker0 Drysdale for this fireside chat. Cybin is a late stage breakthrough neuropsychiatry company committed to revolutionizing mental health care by developing novel next generation treatment options to address the large unmet need. The phase three program for CYBN's lead CYB003 candidate for the injunctive treatment of major depressive disorder is underway and currently dosing. Cybin trades on the NYSE American and CBOE Canada under the ticker CYBN. An ...
Prothena's Late-Stage Study for AL Amyloidosis Fails, Stock Down
ZACKS· 2025-05-27 15:21
Shares of Prothena (PRTA) tumbled 22.5% in after-hours trading on May 23 after it announced the discontinuation of the development of the pipeline candidate, birtamimab.The decision to discontinue comes after the late-stage AFFIRM-AL clinical study evaluating birtamimab in patients with AL amyloidosis did not meet its primary endpoint.The company’s shares have lost 52.5% year to date compared with the industry’s decline of 5%.Image Source: Zacks Investment ResearchMore on PRTA’s BirtamimabBirtamimab was a w ...
Traws Pharma Announces Receipt of FDA Guidance on Tivoxavir Marboxil and Reports Plans for Pursuing Stockpiling for Pandemic Preparedness
Globenewswire· 2025-05-27 12:00
NEWTOWN, Pa., May 27, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today announced receipt of written responses to questions submitted for a Type B pre-Investigational New Drug Application meeting with the U.S. Food and Drug Administration (FDA, the Agency). The FDA provided feedback on development paths fo ...